Heart drug showdown: which statin spares your blood sugar?

NCT ID NCT05705804

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial compares three cholesterol-lowering treatments—pitavastatin alone, pitavastatin plus ezetimibe, and atorvastatin—to see how they affect blood sugar control in people with heart disease and metabolic syndrome (but not diabetes). The main focus is on insulin resistance after 24 weeks. The goal is to find a statin option that protects the heart without raising diabetes risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pitavastatin, ezetimibe, atorvastatin
What this could lead to
If pitavastatin or the combination proves better for blood sugar, doctors may choose these options to lower cholesterol without worsening diabetes risk.
What could go wrong
This is a moderate-sized trial comparing known drugs, so results may not apply to all patients. The effect on glucose is a secondary outcome, and differences may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.